Table 5.
Visual Acuity Outcomes from Baseline to the Three Year Visit*
| Ranibizumab + Prompt Laser treatment N = 144 | Ranibizumab + Deferred Laser treatment N = 147 | |
|---|---|---|
| Change in visual acuity† (letter score) | ||
| Mean±SD | +7 ± 12 | +10 ± 11 |
| Median (25th, 75th percentile) | +8 (+2, +16) | +11 (+4, +17) |
| Difference in mean change from ranibizumab + prompt laser treatment (95% CI) [P value]§ | +2.9 (+0.4, +5.4) [P = 0.02] |
|
| Distribution of change, no. (%) | ||
| ≥30 letter score improvement | 5 (3%) | 7 (5%) |
| 29-25 letter score improvement | 5 (3%) | 8 (5%) |
| 25-20 letter score improvement | 13 (9%) | 15 (10%) |
| 19-15 letter score improvement | 16 (11%) | 17 (12%) |
| 14-10 letter score improvement | 22 (15%) | 35 (24%) |
| 9-5 letter score improvement | 30 (21%) | 22 (15%) |
| Same ±4 letters | 31 (22%) | 30 (20%) |
| 5-9 letters worse | 7 (5%) | 5 (3%) |
| 10–14 letters worse | 7 (5%) | 3 (2%) |
| ≥15 letters worse | 8 (6%) | 5 (3%) |
| Difference in proportion with ≥10 letter improvement from ranibizumab + prompt laser treatment (95% CI) | --- | +13% (+2%, +25%) |
| Relative risk (95% CI) | 1.35 (1.07, 1.69) | |
| P value§ | --- | P = 0.01 |
| Difference in proportion with ≥10 letter worsening from ranibizumab + prompt laser treatment (95% CI) | --- | −5% (−11%, +1%) |
| Relative risk (95% CI) | 0.54 (0.24, 1.23) | |
| P value§ | --- | P = 0.14 |
| Difference in proportion with ≥15 letter improvement from ranibizumab + prompt laser treatment (95% CI) | --- | +5% (−6%, +15%) |
| Relative risk (95% CI) | 1.27 (0.90, 1.78) | |
| P value§ | --- | P = 0.17 |
| Difference in proportion with ≥15 letter worsening from ranibizumab + prompt laser treatment (95% CI) | --- | −2% (−7%, +3%) |
| Relative risk (95% CI) | 0.62 (0.21, 1.85) | |
| P value§ | --- | P = 0.39 |
SD=Standard deviation; CI = Confidence interval.
*
Includes only eyes with visual acuity measurements at baseline and 3-year visit. Visits occurring between 980 and 1204 days (between 140 and 172 weeks) from randomization were included as 3-year visits. When more than one visit occurred in this window, data from the visit closest to the 3-year target date were used.
†
Truncated to ±30 letters.
‡
Based on longitudinal analysis, adjusted for baseline visual acuity.
§
For comparison with ranibizumab + prompt laser treatment.